Van Naarden Jacob

EVP,Pres LLY Oncology&HdCorpBD, EVP & Pres., Lilly Oncology, EVP & Pres., Loxo@Lilly, EVP and CEO Loxo@Lilly, SVP, CEO LoxoONC, Pres LlyONC, Chief Operating Officer, Chief Business Officer · SEC CIK 1661254
Advertisement

Buy track record

How this insider's open-market purchases have performed
100%
of buys now in profit
1 up · 0 down
Avg return since buy+72.8%
Median return+72.8%
Best trade+72.8%
Worst trade+72.8%
Buys scored1
Average return by holding period — separates good entry timing from riding one long winner
After 1 month +13.5% 100% won · 1 trade
After 3 months +55.2% 100% won · 1 trade
After 6 months +58.3% 100% won · 1 trade
After 12 months not elapsed yet
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Aug 13, 2025 LLY $647 $647.4K +5.1% +13.5% +55.2% +58.3% +72.8%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 1 scored trade, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$647.4K
1 trades
Open-market sells
$11.77M
138 trades
Net flow
−$11.12M
Net selling
Total filings
192
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
LLY
Grant/award Van Naarden Jacob · EVP,Pres LLY Oncology&HdCorpBD · Grant/award · filed Feb 11, 2026 ΔOwn +22%
+$5.08M
4,866 sh @ $1,045
LLY
Tax withholding Van Naarden Jacob · EVP,Pres LLY Oncology&HdCorpBD · Tax withholding · filed Feb 3, 2026 ΔOwn −7.7%
−$1.98M
1,909 sh @ $1,037
LLY
Buy Van Naarden Jacob · EVP & Pres., Lilly Oncology · Open-market purchase · filed Aug 13, 2025 ΔOwn +5.1%

Van Naarden Jacob, LLY's EVP & Pres., spent $647.4K of their own money on 1,000 shares at $647, growing their stake 5%.

+$647.4K
1,000 sh @ $647
Advertisement
LLY
Tax withholding Van Naarden Jacob · EVP & Pres., Lilly Oncology · Tax withholding · filed Feb 4, 2025 ΔOwn −9.5%
−$1.14M
1,410 sh @ $811
LLY
Tax withholding Van Naarden Jacob · EVP & Pres., Loxo@Lilly · Tax withholding · filed Feb 2, 2024 ΔOwn −11%
−$1.09M
1,685 sh @ $646
LLY
Tax withholding Van Naarden Jacob · EVP and CEO Loxo@Lilly · Tax withholding · filed Feb 21, 2023 ΔOwn −10.0%
−$440.2K
1,314 sh @ $335
LLY
Tax withholding Van Naarden Jacob · SVP, CEO LoxoONC, Pres LlyONC · Tax withholding · filed Feb 17, 2022 ΔOwn −22%
−$533K
2,186 sh @ $244
LOXO
Disposition to issuer Van Naarden Jacob · Chief Operating Officer · Disposition to issuer · filed Feb 15, 2019 ΔOwn −100%
−$4.47M
19,000 sh @ $235
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −2.2%

Van Naarden Jacob sold $53.9K of LOXO, trimming their stake 2%.

−$53.9K
400 sh @ $135
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −4.5%

Van Naarden Jacob sold $108.7K of LOXO, trimming their stake 4%.

−$108.7K
800 sh @ $136
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −10%

Van Naarden Jacob sold $241.1K of LOXO, trimming their stake 10%.

−$241.1K
1,759 sh @ $137
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −3.3%

Van Naarden Jacob sold $68.9K of LOXO, trimming their stake 3%.

−$68.9K
500 sh @ $138
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −3.4%

Van Naarden Jacob sold $69.6K of LOXO, trimming their stake 3%.

−$69.6K
500 sh @ $139
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −3.8%

Van Naarden Jacob sold $75.8K of LOXO, trimming their stake 4%.

−$75.8K
541 sh @ $140
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −2.2%

Van Naarden Jacob sold $52.2K of LOXO, trimming their stake 2%.

−$52.2K
400 sh @ $131
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −5.6%

Van Naarden Jacob sold $132.2K of LOXO, trimming their stake 6%.

−$132.2K
1,000 sh @ $132
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −5.4%

Van Naarden Jacob sold $119.9K of LOXO, trimming their stake 5%.

−$119.9K
900 sh @ $133
LOXO
Sell Van Naarden Jacob · Chief Business Officer · Open-market sale · filed Dec 12, 2018 ΔOwn −8.8%

Van Naarden Jacob sold $188.5K of LOXO, trimming their stake 9%.

−$188.5K
1,400 sh @ $135

Frequently asked questions

How is Van Naarden Jacob's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Van Naarden Jacob's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.